Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus
CDC Sign-Off Expected In June, Orders To Follow In July
The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.
